Bcl-6

Home Apoptosis Bcl-6

Bcl-6 Products

  • All (5)
  • Bcl-6 Inhibitors (4)
  • New Bcl-6 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S8591 FX1 FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis.
Front Immunol, 2025, 16:1558845
Victoria University of Wellington, 2023,
Haematologica, 2022, 10.3324/haematol.2022.280879
S8250 79-6 (CID5721353) 79-6 (CID5721353) (BCL6 inhibitor) is a BCL6 inhibitor with Kd value of 138 μM.
Cell Rep Med, 2022, 3(9):100744
S8735 BI-3812 BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
Haematologica, 2022, 10.3324/haematol.2022.280879
bioRxiv, 2022, 10.1101/2022.11.03.514941
S6937 BI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor activity.
Phytomedicine, 2024, 133:155944
Haematologica, 2022, 10.3324/haematol.2022.280879
bioRxiv, 2022, 10.1101/2022.11.03.514941
F0774 BCL6 Antibody [L21J6]
S8591 FX1 FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis.
Front Immunol, 2025, 16:1558845
Victoria University of Wellington, 2023,
Haematologica, 2022, 10.3324/haematol.2022.280879
S8250 79-6 (CID5721353) 79-6 (CID5721353) (BCL6 inhibitor) is a BCL6 inhibitor with Kd value of 138 μM.
Cell Rep Med, 2022, 3(9):100744
S8735 BI-3812 BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
Haematologica, 2022, 10.3324/haematol.2022.280879
bioRxiv, 2022, 10.1101/2022.11.03.514941
S6937 BI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor activity.
Phytomedicine, 2024, 133:155944
Haematologica, 2022, 10.3324/haematol.2022.280879
bioRxiv, 2022, 10.1101/2022.11.03.514941

Choose Selective Bcl-6 Inhibitors